申请人:Merck Sharp & Dohme, Ltd.
公开号:US05814644A1
公开(公告)日:1998-09-29
Compound of formula (I), or a pharmaceutically acceptable salt thereof or a prodrug thereof wherein E represents --CH.sub.2 -- or --CH.sub.2 CH.sub.2 --; R represents hydrogen or C.sub.1-6 alkyl; Q represents a moiety of formula Qa, Qb, Qc or Qd which are antagonists of dopamine receptor subtypes within the brain, having a selective affinity for the dopamine D.sub.4 receptor subtype over other dopamine receptor subtypes, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia whilst manifesting fewer side-effects than those associated with classical neuroleptic drugs. ##STR1##
化合物的结构式(I),或其在药学上可接受的盐或前药,其中E代表--CH.sub.2--或--CH.sub.2 CH.sub.2--; R代表氢或C.sub.1-6烷基; Q代表公式Qa、Qb、Qc或Qd的部分,它们是大脑内多巴胺受体亚型的拮抗剂,对多巴胺D.sub.4受体亚型具有选择性亲和力,因此在治疗和/或预防精神分裂症等精神疾病方面具有益处,同时表现出比与经典神经阻滞药物相关的副作用更少。